Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
EYPT.US
id: 960

EyePoint (EYPT) Subpoena Case

  • In Aug 2022, EyePoint disclosed receiving a subpoena from the U.S. Attorney's Office for the District of Massachusetts.

  • On it, $EYPT fell 10%, losing $56M+ shareholder value.

  • Investors may have grounds to suspect EyePoint of hiding regulatory issues.

On August 30, 2022, after market hours, EyePoint disclosed that it had received a subpoena from the U.S. Attorney's Office for the District of Massachusetts seeking documents regarding sales practices for its postoperative inflammation treatment, DEXYCU

On this news, $EYPT fell 10% and lost over $56 million of its market capitalization, seriously damaging shareholders.

Considering all the information, investors might have grounds to suspect that EyePoint and its executives failed to disclose regulatory setbacks, which consequently led to their losses.

The case is already under investigation by at least one of the reputable law firms.

Case Status
Inactive Investigation
Alleged Offence
Misleading Statements, 
Failure to Disclose, 
Omissions
Suspected Party
Directors, 
Management
Security Type
Stocks
Trade Direction
Long
Shock Event Date
08/31/2023